Akylox Therapeutics ApS

CVR 44974045 · Private limited company (ApS) · Active · Medium risk

Akylox Therapeutics ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 1 annual report has been published. The latest annual report (31 Dec 2025) shows equity of DKK 11.3m and a net result of DKK -21.0m.

Bankruptcy risk for Akylox Therapeutics ApS

1.4%
probability of bankruptcy within 12 months
Medium risk

1.0 × the average (1.41%) · higher risk than 77% of active Danish companies

Lowest riskHighest risk

Increases the risk

Age (years)2 yrs · bankruptcy rate 18.9%2.1×
Published annual reports1 · bankruptcy rate 18.7%2.1×
Return on assets< -20% · bankruptcy rate 16.7%1.9×
Going-concern uncertaintyYes · bankruptcy rate 16.3%1.9×
Time at current address1 yrs · bankruptcy rate 14.0%1.6×
Moves in the last 2 years1 · bankruptcy rate 12.7%1.4×
Number of CEOs0 · bankruptcy rate 12.7%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×

Reduces the risk

Equity vs. share capital5+× · bankruptcy rate 2.5%0.28×
Equity ratio60%+ · bankruptcy rate 3.3%0.38×
Current ratio200%–500% · bankruptcy rate 3.4%0.39×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×
Negative equityNo · bankruptcy rate 5.1%0.58×
Share of late annual reports< 0.01% · bankruptcy rate 5.2%0.59×
Auditor's statementCompilation · bankruptcy rate 5.6%0.64×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
44974045
Status
Active
Company type
Private limited company (ApS)
Founded
(2 years)
Address
c/o Symbion Frederiksberg, Nordre Fasanvej 215
2000 Frederiksberg
Municipality
Frederiksberg
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 100k
Auditor
EY Godkendt Revisionspartnerselskab
Audit opted out
No

Warning signs

Annual reports filed late0 of 1
Missing annual reportNo
Negative equityNo
Equity ratio77.7%
Current ratio369%
Moves (last 2 years)1
CEO changes in total2
CEO's previous bankruptcies0
Other companies at the address111
Going-concern uncertaintyYes

Financials and key figures

Financial year2025
Gross profitDKK -2.4m
Net profitDKK -21.0m
EquityDKK 11.3m
Total assetsDKK 14.5m
CashDKK 8.5m
Short-term debtDKK 3.2m
Avg. employees1

Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · EY Godkendt Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
5 Jul 2024 – 31 Dec 2025173

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOAlexander Thomas Hagen Flohr
CEOSebastian Kim Lugert
BoardGabor GyulvesziCurrent
BoardMartin BondeCurrent
BoardButrint AliuCurrent
BoardPablo Gabriel Cironi LopezCurrent
BoardMorten Døssing
BoardMaurits Jacob-Jan Brandt
BoardAlexander Thomas Hagen Flohr
BoardMatthias Paul Wymann
BoardSøren Sylvester Skjærbæk
Owner (5%)Alexander Thomas Hagen FlohrCurrent
Owner (5%)Sebastian Kim LugertCurrent
Owner (33%)Novo Holdings A/SCurrent
Owner (10%)Danmarks Eksport- og InvesteringsfondCurrent
Owner (5%)Dennis Gregory GillinghamCurrent
Owner (10%)Matthias Paul WymannCurrent
Owner (5%)Pureos Bioventures 2, LPCurrent
Owner (5%)Criteria Bio Ventures SICC S.A.Current
Owner (15%)Alexander Thomas Hagen Flohr
Owner (25%)Dennis Gregory Gillingham
Owner (33%)Matthias Paul Wymann
Owner (15%)Sebastian Kim Lugert
Owner (20%)Novo Holdings A/S
Owner (10%)Alexander Thomas Hagen Flohr
Owner (15%)Dennis Gregory Gillingham
Owner (20%)Matthias Paul Wymann
Owner (10%)Sebastian Kim Lugert
Owner (5%)Universität Basel
Owner (5%)Danmarks Eksport- og Investeringsfond
Owner (33%)Novo Holdings A/S
Owner (10%)Danmarks Eksport- og Investeringsfond
Owner (10%)Dennis Gregory Gillingham
Owner (15%)Matthias Paul Wymann
AuditorEY Godkendt RevisionspartnerselskabCurrent
FounderAlexander Thomas Hagen FlohrCurrent
FounderDennis Gregory GillinghamCurrent
FounderMatthias Paul WymannCurrent
FounderSebastian Kim LugertCurrent

Address history (2 moves)

c/o Symbion Frederiksberg, Nordre Fasanvej 215, 2000 Frederiksberg
Ole Maaløes Vej 3, 2200 København N
Damhaven 5C, 7100 Vejle

Other companies at the same address

Similar companies in Frederiksberg

Questions and answers about Akylox Therapeutics ApS

Has Akylox Therapeutics ApS gone bankrupt?

No, Akylox Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Akylox Therapeutics ApS?

Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.

Who is the auditor of Akylox Therapeutics ApS?

Akylox Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.

When was Akylox Therapeutics ApS founded?

Akylox Therapeutics ApS was founded on 5 July 2024.

What is the equity of Akylox Therapeutics ApS?

Equity was DKK 11.3m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.